Global health technology and human data sciences company, IQVIA has announced two multi-million-pound investments as part of the UK Government’s Second Life Sciences Sector Deal.
One of the UK’s leading businesses within the life sciences space has committed an investment package totaling £46m in the UK economy in an update to the Life Sciences Sector Deal announced by the UK Government in November 2017 as part of the UK Industrial Strategy. The package includes two key investments – £24m in a new “Prime Site” in the North of England and £20m in a new collaboration with Genomics England. The package was unveiled by the Government in a parliamentary statement.
IQVIA, facilitated by the National Institute for Health Research (NIHR), has committed to opening a fourth UK Prime Site to focus on the delivery of life-changing clinical research across the North of England, which includes investing up to £24m over five years with plans to employ over 50 additional highly-skilled staff to drive additional trials across the UK. The Northern Prime Site will include NHS research-ready hospitals across the Greater Manchester, Leeds and Sheffield region. The new site will embrace a data-enabled approach to the design and delivery of hundreds of additional clinical trials and real-world evidence studies which will benefit thousands of NHS patients. IQVIA currently conducts 25% of all commercial clinical trials within the NHS.
In addition, IQVIA will invest £20m during the next five years in a new partnership with Genomics England to develop services to allow authorised researchers to run studies enabling faster and more efficient drug research, and to develop more robust evidence to support treatment value and greater access to personalised medicines for NHS patients.
This Second Life Sciences Sector Deal is the extension of a previous set of deals announced alongside the UK’s Industrial Strategy in November 2017. Each deal represents a new strategic and long-term partnership with Government, backed by private sector co-investment and will drive investment in the UK’s world-leading research infrastructure and boost productivity within the sector.
Professor Sir John Bell, Chair of the Life Science Industrial Strategy Advisory Board, said: “Investments by well regarded, global companies like IQVIA demonstrate that the UK’s science base is truly world-leading and an exceptional national strength. Such investments will deliver the next wave of innovation that will benefit NHS patients, transform the UK healthcare system, and generate economic growth and improved productivity.”
Secretary of State for Business, Enterprise and Industrial Strategy, Rt Hon Greg Clark MP added: “From the first vaccine to the discovery of DNA, the UK has always been at the forefront of medical endeavour and healthcare innovations. That is why we are building on our unique strengths by placing life sciences at the centre of our modern Industrial Strategy, backed by the biggest increase in public research and development investment in UK history.
“This is our modern Industrial Strategy in action as we work hand in hand with industry to ensure the UK remains the go-to destination for launching new businesses, new discoveries and treatments to benefit health around the world.”
Tim Sheppard, Senior Vice President (SVP) and General Manager, Northern Europe IQVIA, said: “This landmark investment package is a demonstration of IQVIA’s confidence in, and its commitment to, the future of the UK life sciences industry. The Life Sciences Sector Deal announced by the UK Government last year was a major step forward for the industry, and IQVIA is proud to play our part in ensuring its future success through this historic and transformative investment.
“Not only will the investment bolster the economy in the North of England through our ambition to create 50 new high-skilled jobs, but the additional research capacity in developing new clinical trials and our partnership with Genomics England will break new ground in our ability to support the delivery of innovative medicines that will be life changing for many NHS patients.
“IQVIA believes in the UK’s potential to be a unique bioscience centre of excellence within the life sciences space, and this investment further supports the UK Government and the industry’s aim to ensure this potential is realised. Importantly, this is also a platform from which we can build even greater sector momentum behind the overall UK Industrial Strategy.”
Niall Dickson, Chief Executive of the NHS Confederation, which represents organisations across the healthcare sector, said: “The continued investment in the UK economy through the new Life Sciences Sector Deal is welcome. It is pleasing to see the focus on the increasingly important issue of early disease detection – something that will no doubt benefit all our communities, especially given the challenges associated with an ageing population.
“The fact that a second deal has been secured shows that in this important area, government, industry and the NHS are able to continue to collaborate to help communities to be both better and better off. The NHS depends on a healthy economy and vice versa, and the life sciences sector in particular is a crucial component of UK Plc.
“Our main priority has been to ensure the NHS is a full partner in this work, and it is gratifying to see the deal reflect this need. Our members in particular want to reflect the outcomes and benefits from collaborating around data, genomics, skills and research in our service provision. If we are to fulfil the potential of life sciences, the NHS must be supported, encouraged and resourced to play its part.
“This sector deal is just one part of the wider Industrial Strategy. The NHS Confederation is the only national health organisation working across the UK to support its members to engage in this important policy and we will continue to highlight the close links between health and wealth.”